Research

We rounded up a few research highlights from the 2024 Congress of the European Society for Medical Oncology (ESMO), held recently in Madrid, Spain. Belzutifan continues to outperform targeted therapy in advanced kidney cancer Belzutifan outperformed targeted therapy with everolimus in certain advanced kidney cancer patients, who experienced longer times till their tumors began growing again with the novel hypoxia-inducible factor 2a…

People with metastatic kidney cancer who already received one or two lines of treatment that included immunotherapy did not fare better when offered an additional round of immunotherapy after their cancer progressed. The results from the phase 3 TiNivo-2 trial, presented at the recent European Society of Medical Oncology (ESMO) meeting in Barcelona, Spain, compared combination treatment with the targeted…

This is a guest post by Liam Piscetelli, the KCA’s 2024 Research Intern. Liam Piscetelli For the past 8 months, I have interned with the KCA as a research intern. As a student working towards their Masters of Public Health with a concentration in Applied Epidemiology from the University of Arizona, this opportunity to work with the KCA proved to…

A retrospective analysis of just over 100 people with metastatic chromophobe renal cell carcinoma (RCC) showed that patients given first-line doublet therapy – two drugs simultaneously – had superior outcomes compared to patients given a single therapy. [ASCO 2024, Abstract 4512] https://www.youtube.com/watch?v=AvyqrQc9Crk&t=187s This trial, conducted by Dr. Sahil Doshi of Memorial Sloan Kettering Cancer Center and presented at the 2024 meeting…

Among a trio of biomarker studies presented at the 2024 meeting of the American Society of Clinical Oncology, one stood out as having potential predictive and prognostic value for some kidney cancer patients. Dr. Laurence Albiges presenting a biomarker analysis of the IMmotion010 trial at ASCO 2024. Presented by Dr. Laurence Albiges of the Institut Gustave Roussey in France, kidney…

Dr. Salvatore La Rosa, KCA Chief Scientific Officer Welcome to our new blog series where we distill the latest in kidney cancer clinical trials into essential updates for patients, caregivers, and those tracking advancements in this field. With 87 new interventional studies since January 2023, the research landscape is vibrant and full of potential. Here, we translate complex research into…

The Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts recently recognized the Kidney Cancer Association (KCA) for supporting researchers at the institution with over $1 million in funding. KCA’s name was placed on the DFCI’s Benefactors Wall, located on the third floor of the DFCI's Yawkey Center for Cancer Care. “We are so pleased to honor KCA’s tremendous support of kidney…

This is a guest post by D’Ann George, PhD, Medical Writer. Some kidney cancers are so rare that clinicians don’t know enough about them to determine what treatments should be standard, or even to predict how the disease will behave over time. Among these rare renal cell carcinoma (RCC) types are papillary, chromophobe, sarcomatoid, and hereditary leiomyomatosis and renal cell…

Dr. Kaushal Asrani received a 2024 Kidney Cancer Association Trailblazer Award in partnership with Joey's Wings Foundation for research on "Therapeutic Targeting of EGFR and HER2 in Translocation Renal Cell Carcinoma". Dr. Asrani is a research associate at the Johns Hopkins School of Medicine in Baltimore, Maryland. We spoke with him about his research and the impact it could have…

We rounded up a few research highlights from the 2024 ASCO Genitourinary Cancers Symposium (ASCO GU), held recently in San Francisco, California. Adjuvant immunotherapy improved survival after nephrectomy and could be new standard of care Researchers are touting a potential new standard of care following surgery for clear cell renal cell carcinoma (RCC) patients with an intermediate- to high-risk of recurrence who…